Melanotan II: what the research says.

Melanotan II (often abbreviated MT-II or MT2) is a cyclic synthetic heptapeptide designed as a stable, potent analog of alpha-melanocyte-stimulating hormone, the endogenous peptide that activates melanocortin receptors in skin and brain tissue. It was synthesized at the University of Arizona in the 1980s by a team led by Victor Hruby and Mac Hadley, with the original goal of producing a research tool for studying pigmentation biology and the possibility of induced melanin production as a photoprotective strategy against ultraviolet skin damage.

Structurally, MT-II is a cyclic lactam analog of the alpha-MSH core sequence, with modifications that increase receptor affinity, extend half-life, and resist enzymatic degradation. Its potency at melanocortin receptors is substantially higher than the natural hormone, which is why it became a workhorse compound in melanocortin pharmacology research.

Melanotan II should not be confused with two related but distinct molecules. Melanotan I (afamelanotide), now marketed in some jurisdictions as Scenesse, is a separate, linear MSH analog approved for the rare disorder erythropoietic protoporphyria. Bremelanotide (PT-141), which is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, is a metabolite-derived analog with a different receptor selectivity profile. MT-II is none of these. It has no FDA approval for any indication.

In published research settings, MT-II has been studied via subcutaneous injection, typically in small doses to characterize pharmacologic effects. There is no FDA approval, no FDA-approved labeling, and no standardized dosing protocol that has been validated through international regulatory review.

Gray-market products labeled as Melanotan II are widely available online and are generally sold as research chemicals without pharmaceutical-grade quality assurance. Purity, identity, and contamination risk are unknown for these products, and there is no manufacturer accountable to a regulatory authority.

This is research context, not prescribing guidance. PepScribe does not currently offer Melanotan II, and this information should not be interpreted as a dosing recommendation or instruction for self-administration.

Melanotan II is not approved by the US Food and Drug Administration for any medical indication. The FDA has issued warning letters to companies marketing Melanotan II products, which is the relevant historical context for any conversation about the compound. The agency has explicitly described unapproved injectable Melanotan II products as illegally marketed drugs.

Melanotan II is on the FDA April 15, 2026 Category-unclassified peptide list, the cohort of compounds that were removed from FDA Category 2 but were not placed on Category 1. Their final classification remains pending the Pharmacy Compounding Advisory Committee review process, with most reviews scheduled for the July 23 to 24, 2026 meeting and the remainder by the end of February 2027. Some compounding pharmacies have begun producing Category-unclassified peptides on the theory that removal lifts prohibition, while regulatory ambiguity persists.

Outside the United States, MT-II is restricted in multiple jurisdictions. The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has taken enforcement action against unlicensed Melanotan products. The Therapeutic Goods Administration (TGA) in Australia lists Melanotan II as a Schedule 4 prescription-only medicine, which it is not legally available as. Various European authorities have also issued public health warnings against unregulated MT-II products.

Online gray-market products labeled as Melanotan II are unregulated research chemicals without pharmaceutical-grade quality assurance. They sit outside the compounding pharmacy framework entirely.